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ORIGINAL RESEARCH COMMUNICATION
Copper and Myeloperoxidase-Modified LDLs
Activate Nrf2 Through Different Pathways
of ROS Production in Macrophages
Damien Calay,1 Alexandre Rousseau,2 Laurine Mattart,1 Vincent Nuyens,2
Ce´dric Delporte,3 Pierre Van Antwerpen,3 Nicole Moguilevsky,4 Thierry Arnould,1
Karim Zouaoui Boudjeltia,2 and Martine Raes1
Abstract
Low-density lipoprotein (LDL) oxidation is a key step in atherogenesis, promoting the formation of lipid-laden
macrophages. Here, we compared the effects of copper-oxidized LDLs (OxLDLs) and of the more physiologically
relevant myeloperoxidase-oxidized LDLs (MoxLDLs) in murine RAW264.7 macrophages and in human peripheral
blood monocyte-derived macrophages. Both oxidized LDLs, contrary to native LDLs, induced foam cell formation
and an intracellular accumulation of reactive oxygen species (ROS). This oxidative stress was responsible for the
activation of the NF-E2-related factor 2 (Nrf2) transcription factor, and the subsequent Nrf2-dependent over-
expression of the antioxidant genes, Gclm and HO-1, as evidenced by the invalidation of Nrf2 by RNAi. MoxLDLs
always induced a stronger response than OxLDLs. These differences could be partly explained by specific ROS-
producing mechanisms differing between OxLDLs and MoxLDLs. Whereas both types of oxidized LDLs caused
ROS production partly by NADPH oxidase, only MoxLDLs-induced ROS production was dependent on cyto-
solic PLA2. This study highlights that OxLDLs and MoxLDLs induce an oxidative stress, through distinct ROS-
producing mechanisms, which is responsible for the differential activation of the Nrf2 pathway. These data clearly
suggest that results obtained until now with copper oxidized-LDLs should be carefully reevaluated, taking into
consideration physiologically more relevant oxidized LDLs. Antioxid. Redox Signal. 13, 1491–1502.
Introduction
Reactive oxygen species (ROS) are products of normalcell metabolism and play a major physiological role in
intracellular signaling and regulation, such as the regulation
of vascular tone, cell adhesion, or immune responses (10).
However, an excessive and=or sustained increase in ROS
production results in damage to cell structures (10, 40). In
order to cope with an excess of ROS and the subsequent oxi-
dative stress, humans have developed cellular mechanisms to
maintain redox homeostasis. These involve antioxidant de-
fenses such as glutathione (GSH), the major thiol antioxidant
and redox buffer of the cell (11). Elevated ROS concentrations
also lead to the activation of the NF-E2-related factor 2 (Nrf2)
transcription factor, which is a central protein in the cellular
response to oxidative stress. Once activated by ROS, Nrf2
strongly binds on DNA to the Antioxidant Response Element
(46) sequence and, by this way, regulates the expression of
protective genes such as the phase II drug metabolizing en-
zymes, aswell as the regulatory subunit of glutamate-cysteine
ligase (Glcm) and heme oxygenase-1 (HO-1) (16). Gclm is the
rate-limiting enzyme in GSH synthesis (11). HO-1 is the rate-
limiting enzyme in the degradation of heme, and induction of
this enzyme causes cells to reduce their pools of heme
and heme-containing proteins, eliminating potential pro-
oxidants. Moreover, the by-products of this reaction—
biliverdin and carbon monoxide—have antioxidant as well as
anti-inflammatory properties (23, 30). Thus, it appears that
Nrf2 is a key protein in the cellular response to oxidative stress
and that its target genes (e.g., Gclm andHO-1) are induced for
the purpose of coping with oxidative stress (19).
Despite these antioxidant defenses, when the level of ROS
exceeds the antioxidant capacity of the cell, the intracellular
redox homeostasis is altered and oxidative stress ensues.
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Oxidative stress is considered to play a pivotal role in various
pathological conditions, involving cardiovascular diseases,
cancer, neurological disorders, and aging (35, 40). In partic-
ular, excessive ROS production has been implicated in ath-
erogenesis and throughout the development of this disease
(35). Atherosclerosis is the major cause of heart disease and
stroke, and is commonly viewed as a chronic inflammatory
disease in which macrophages play a key role (18, 22). Actu-
ally, oxidative modifications of low-density lipoproteins
(LDLs) contribute to the accumulation of cholesterol-loaded
macrophages, termed ‘‘foam cells,’’ that are a hallmark of the
disease (18, 22, 36).
Nonetheless, although lipoprotein oxidation is well recog-
nized to be implicated in atherogenesis (3, 36), the physio-
logically relevant pathways mediating these oxidative
modifications have not yet been unambiguously identified.
In vitro, the most widely studied model of LDLs oxidation
involves copper ions. Indeed, free metal ions such as iron and
copper have been detected in atherosclerotic lesions, and high
concentrations of metal ions are potent catalysts for in vitro
LDL oxidation. However, the concentrations of copper sulfate
currently used in vitro to oxidize LDL (e.g., 10–20mM) largely
exceed physiological concentrations and lead to very different
composition, structural, and biochemical features of the oxi-
dized LDL (47).
That is why more recently alternative LDL oxidative
pathways have been proposed involving for instance
lipoxygenases (41), NAPDH oxidase (13), or myeloperoxidase
(MPO) that focused our attention.MPO is certainly not the only
enzyme mediating LDL oxidation in vivo, but there is accumu-
lating evidence suggesting its implication in this process.
Indeed, MPO, its specific by-product—3-chlorotyrosine—and
MPO-oxidized LDL have been detected in human atheroscle-
rotic lesions (8, 12, 28). Moreover, MPO strongly binds to
Apo-B100 of LDL, retaining its catalytic activity. This could
potentially enhance site-directed oxidation of the ApoB-100 of
LDL and limit scavenging of reactive oxygen species by anti-
oxidants (5). This enzyme may therefore represent one relevant
pathway for LDL oxidation in vivo. Even though we are aware
that MPO is not the only enzyme implicated in the in vivo
modifications of LDL and that MoxLDL are only one kind of
modified LDLs that can be foundwithin atherosclerotic lesions,
we decided to focus on LDL oxidation by MPO, which consti-
tutes one of the more physiological mechanisms implicated in
LDL oxidation (32).
The aim of this study was to highlight the differential ef-
fects of the copper-oxidized LDLs (OxLDLs) and of the phys-
iologically more relevant myeloperoxidase-oxidized LDLs
(MoxLDLs) in macrophages, using murine RAW264.7 macro-
phages, but also human monocyte-derived macrophages. We
showed that both OxLDLs and MoxLDLs accumulate in
macrophages, leading to foam cell formation, and induce an
intracellular accumulation of ROS that is responsible for the
activation of the Nrf2 transcription factor. Both OxLDLs and
MoxLDLs also induce a ROS- and Nrf2-dependent over-
expression of the antioxidant genes,Gclm andHO-1. However,
MoxLDLs always induce a stronger response than OxLDLs,
both in the generation of the oxidative stress and in the in-
duction of the Nrf2 defensive pathway. We showed that this
quantitative difference in the response to oxidized LDLs could
be explained in part by qualitative differences in the ROS-
producing mechanisms between OxLDLs and MoxLDLs.
Materials and Methods
Please see the supplemental data at www.liebertonline
.com=ars for additional details.
Cell culture
The murine RAW264.7 macrophage cell line was obtained
from the American Type Culture Collection (Manassas, VA)
and grown in DHG-L1 medium (Dulbecco’s modified Eagle’s
mediumþhigh glucose (4.5 g=l)þNaHCO3 (1.5 g=l)) con-
taining 10% of heat-inactivated fetal calf serum (Gibco BRL).
RAW264.7 macrophages were incubated for 1 h in DHG-L1
containing 1% of heat-inactivated serum before any treat-
ment. Inhibitors and Trolox experiments were performed by
incubating the cells with the molecules for 1 h prior to stim-
ulation with LDLs. Cell viability was estimated using the
classical LDH assay, and a maximal cytotoxicity of 30% was
observed after 48 h of incubation with 200 mg=ml of oxidized
LDLs. Peripheral blood mononuclear cells (PBMC) were iso-
lated using Ficoll (Histopaque-1077, Sigma Diagnostics,
St. Louis, MO) following the manufacturer’s instructions.
Briefly, heparinated blood was half-mixed with HBSS (Lonza,
Belgium) and layered on Ficoll in a 50ml centrifuge conical
tube. After centrifugation at 400 g for 30min at room temper-
ature, the upper layer containingplasmawas discarded and the
interface containing the mononuclear cells (i.e., lymphocytes
and monocytes) was collected. After two washes in HBSS,
the mononuclear cells pellet was resuspended in RPMI
1640þ 1.5mM L-glutamine (Lonza). After cell counting,
mononuclear cells were diluted at a concentration of 100,000
cells=ml in RPMI 1640þ 1.5mM L-glutamine, 1mM sodium
pyruvate, 50mM 2-mercaptoethanol, and 1% nonessential
amino acids supplemented with 10% heat-inactivated autolo-
gous serum (complete RPMI) and seeded in 6-well, 12-well,
or 24-well plates. After 1h, lymphocytes were washed away
by PBS and monocytes were incubated in complete RPMI in
the presence of M-CSF 20ng=ml (R&D Systems, Abingdon,
UK) for 5 days in a humidified incubator at 378C and 5%
CO2 for macrophage differentiation (33). Medium was chan-
ged with complete RPMI containing fresh M-CSF at day 3.
LDL isolation and oxidation
Native LDLs (NatLDLs) were obtained by sequential den-
sity gradient ultracentrifugation from plasma of healthy
blood donors. The concentration of NatLDL in PBS was ad-
justed to 1mg=ml before incubation with 10 mM copper sul-
fate for 24 h at 378C. The oxidation was stopped by the
addition of 25mM butylated hydroxytoluene and incubation
on ice for 1 h. MoxLDLwere generatedmixing 8ml of HCl 1M
(final concentration: 4mM), 45ml of recombinant humanMPO
(rhMPO) 92.4U=ml (final relative activity: 4.2U, or 2.6U=mg
LDL), a volume containing 1600 mg LDL and 40 ml of H2O2
50mM (final concentration: 1mM). The volume was adjusted
to 2ml with PBS containing 1 g=L of EDTA, at pH 6.5. Simi-
larly, for the generation of MoxLDL-C, 8 ml of HCl 1 M (final
concentration: 4mM), 90 ml of MPO 92.4U=ml (final relative
activity: 8.4U, or 5.2U=mg LDL), a volume containing
1600 mg LDL, 40ml of H2O2 50mM (final concentration: 1mM)
were mixed. The volume was adjusted to 2ml with PBS
containing 1 g=L of EDTA, at pH 4. rhMPO was provided by
the Experimental Medicine Laboratory (ULB 222 Unit, CHU
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Charleroi, Belgium). The oxidation reaction for the generation
of MoxLDL and MoxLDL-C was immediately performed at
378C for 5 and 20min, respectively, and stopped by incuba-
tion on ice to inhibit the MPO enzymatic activity. NatLDLs,
OxLDLs, MoxLDLs, and MoxLDL-C were desalted against
RPMI-1640 without glutamine (Cambrex, Belgium) by using
PD-10 desalting columns (GE Healthcare). LDLs were sterile
filtered (0.2 mm), stored in the dark at 48C and used within
4 days. The LDL concentration was determined by the Lowry
method and used at a concentration of 200mg=ml, concen-
tration effectively observed in patients suffering from chronic
obstructive pulmonary disease (COPD) (49) and in patients
under dialysis (39).
LDL characterization
Determination of purity and alteration in negative charge
in LDL preparations was carried out by an agarose gel elec-
trophoresis. The relative electrophoretic mobilities of OxLDL,
MoxLDL, and MoxLDL-C were 1.42" 0.17, 1.55" 0.14, and
1.44" 0.16, respectively, in comparison to NatLDL. As pre-
viously described in Zouaoui Boudjeltia et al. (48), the MDA-
HNE content, as determined by the TBARS assay, was clearly
higher in copper-oxidized LDL compared to native LDL,
whereas it was similar in MoxLDL. The extent of lipid per-
oxidation of LDL was further estimated by a fluorescence-
based method, according to Yagi et al. (42) (see supplemental
data; Fig. 8A.). Compared to NatLDLs, OxLDLs showed an
increased lipid peroxidation while it was only slightly in-
creased in MoxLDLs. The lipid peroxidation content of
MoxLDLs-C was intermediate as it was clearly higher than in
MoxLDLs but was much more moderate compared to
OxLDLs.
Statistics
SigmaStat software ( Jandle Scientific, Germany) was used
for the analysis. Data are presented asmeans" SEM andwere
evaluated by one-way ANOVA, using the Holm-Sidak
method.
Results
Macrophages incubated with MoxLDLs accumulate more
lipid droplets and display a very distinct morphology
compared to OxLDLs-incubated macrophages
The ability of the murine RAW264.7 macrophages to ac-
cumulate modified LDLs and consequently to differentiate
into foam cells was first assessed. RAW264.7 macrophages
were therefore treated with native or oxidized LDLs for 48 h
before lipid staining by Oil Red O (Sigma, St. Louis, MO) or
Bodipy! (Invitrogen, Carlsbad, CA) Fig. 1A, top and middle
panels, respectively). Both stainings clearly show that mac-
rophages internalizeNatLDLs in a regulatedmanner as only a
small number of intracellular lipid droplets is observed.
Indeed, native LDLs are recognized by the LDL receptor
(LDL-R) that is downregulated by the intracellular cholesterol
content through a signaling pathway implicating SREBP (45).
Thus, the internalization of native LDLs is tightly controlled
and never leads to an excessive accumulation of intracellular
lipid droplets and subsequent foam cell formation. On the
opposite, large amounts of lipid droplets are observed
throughout the cytoplasm of both OxLDLs- and MoxLDLs-
incubated macrophages (Fig. 1A). A quantification of the Oil
RedO staining after 30min to 48 h (Figure 1B) confirmed these
observations, with OxLDLs and MoxLDLs, respectively,
causing an intracellular 2.9" 0.26 and 4.1" 0.37 fold accu-
mulation of lipids after 48 h compared to control cells. A sig-
nificant accumulation of lipid droplets was observed after
48 h of incubation with NatLDLs, probably due to some oxi-
dation of the NatLDL in the contact of the cells for long pe-
riods of time. However, a significant accumulation of lipid
droplets was already observed after 24 h and 2h of incubation
with OxLDLs or MoxLDLs, respectively. Moreover, the
MoxLDLs-induced accumulation of lipids was significantly
higher than the one caused by OxLDLs. In addition, whereas
RAW264.7 macrophages incubated with OxLDLs appeared
very rounded, a more typical spread morphology of macro-
phages, with long cytoplasmic extensions, was observed in
the presence of MoxLDLs (Fig. 1A, top panel). The accumu-
lation of intracellular lipid droplets was confirmed in human
M-CSF differentiated macrophages prepared from PBMC,
although more difficult to visualize, due to larger amounts of
lipids in control cells and in NatLDLs-treated cells (Fig. 1A,
bottom panel). However, the quantification of the Oil Red O
staining showed that the incubation with both oxidized LDL
induced an accumulation of intracellular lipid droplets, but to
a lesser extent than in RAW264.7 macrophages (Fig. 1C).
Moreover, it seems that the internalization was more impor-
tant in MoxLDLs-treated macrophages than in OxLDLs-
incubated cells, as observed for the murine RAW264.7 cells.
Oxidized LDLs induce an intracellular oxidative
stress in RAW264.7 and in human
PBMC-derived macrophages
Oxidized LDLs are claimed to largely contribute to the
oxidative context of atherosclerosis (36). To directly assess this
oxidative stress, RAW264.7 and PBMC-derived macrophages
were incubated with native or oxidized LDLs (200 mg=ml) and
the intracellular accumulation of ROS was monitored (Figs.
2A and 2B, respectively). In RAW264.7 macrophages, where
NatLDLs had no effect, an accumulation of ROSwas observed
in the presence of oxidized LDLs. However, the oxidative
stress produced by the MoxLDLs was more intense than the
one caused by OxLDLs (Fig. 2A). Trolox, an antioxidant and
hydrophilic vitamin E analogue, totally abolished the oxi-
dized LDL-induced ROS accumulation (Fig. 2A). This accu-
mulation of ROS was also observed in PBMC-macrophages
incubated with OxLDLs or MoxLDLs, whereas in incubations
with NatLDLs, a decrease in oxidative stress was observed
(Fig. 2B). Moreover, a clear difference was observed between
OxLDLs and MoxLDLs-induced ROS accumulation as
OxLDLs only induced a slight increase in ROS production,
whereas it was more intense for MoxLDLs (Fig. 2B).
Oxidized LDLs activate the transcription factor
Nrf2 in a ROS-dependent manner
AsNrf2 is a well-known ROS-activated transcription factor
(16, 19), its activation state in RAW264.7 macrophages after
incubation with native or oxidized LDLs was assessed using a
reporter plasmid. The stimulation of macrophages with oxi-
dized LDLs induced the activation of Nrf2 (Fig. 3),whereas,
similarly as for the ROS production, the incubation of mac-
rophages with NatLDLs did not. Moreover, MoxLDLs
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triggered a significantly stronger activation of Nrf2 than
OxLDLs (Fig. 3). The regular addition of Trolox significantly
decreased the oxidized LDLs-induced activation of Nrf2 (Fig.
3), which suggests a prevalent role of ROS in this activation.
Oxidized LDLs induce the overexpression
of the antioxidant genes, Gclm and HO-1
Following oxidative stress, cells activate a global tran-
scriptional response, notably through Nrf2, in order to
counteract the accumulation of ROS. Among the genes in-
volved in this response, Gclm and HO-1 play a crucial role in
the generation of antioxidants such as glutathione and bili-
rubin. The relative abundance of the mRNA for these two
genes was evaluated after incubation of the RAW264.7 mac-
rophages with 200mg=ml of native or oxidized LDLs (Figs. 4A
and 4B). NatLDLs were unable to induce an overexpression
neither of Gclm nor HO-1, in comparison to control cells.
However, the mRNA abundance of both genes was increased
after incubation with OxLDLs or MoxLDLs (Figs. 4A and 4B).
FIG. 1. Differential lipid accumulation in macrophages incubated with OxLDLs or MoxLDLs. RAW264.7 cells (A, top
and middle panels, B) and human PBMC-derived macrophages (A, bottom panel, and C) were incubated for 48 h with native
or oxidized LDLs (200 mg=ml), stained with Oil Red O (A, top and bottom panels) or Bodipy (A, middle panel) and visualized
with an optical (objective 20X) or a confocal microscope, respectively. (B) The absorbance of Oil Red O staining was
normalized by the quantity of cells. Results represent the mean of four replicates" SEM. N.S.¼ nonsignificant, ***p< 0.001
OxLDL or MoxLDL vs. control; ###p< 0.001 OxLDL vs. MoxLDL.
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For Gclm, a peak of overexpression was observed after 6 h of
incubation with OxLDLs or MoxLDLs, but again differences
between the OxLDLs-induced and MoxLDLs-induced over-
expression were remarkable throughout the kinetics (Fig. 4A).
Regarding HO-1, the maximal overexpression was detected
after 4 h of incubation with MoxLDLs, whereas the peak of
expression was more attenuated and observed after 6 h of
incubation with OxLDLs. Moreover, a second wave of over-
expression was observed after 12 h of incubation of the mac-
rophages with MoxLDLs, which was not seen with OxLDLs
(Fig. 4B.). The overexpression of HO-1 was also observed
in human PBMC-derived macrophages incubated with
200 mg=ml of oxidized LDL for 6 h (Fig. 4C). This over-
expression was not observed when the cells were incubated
with NatLDLs. Moreover, MoxLDLs induced a stronger
overexpression of HO-1 than OxLDLs. In RAW264.7 macro-
phages, the overexpression of HO-1 and Gclm after oxidized
LDLs treatment was confirmed at the protein level (Fig. 4D).
Whatever the time of incubation (from 2 to 24 h), NatLDLs did
never induce an increased abundance neither of Gclm nor
HO-1, in comparison to control cells (Fig. 4D). However, the
abundance of Gclm was increased and maximal after 12 h of
incubation with OxLDLs or MoxLDLs, and much more pro-
nounced in the presence of MoxLDLs (Fig. 4D). While
MoxLDLs induced a peak of abundance for HO-1 between 8
and 12h of incubation, this peak was more attenuated and
clearly observed after 8 h of incubation with OxLDLs. More-
over, contrary to MoxLDLs, the OxLDLs-induced HO-1
overexpression returned to basal levels after 24 h (Figure 4D).
These observations were confirmed by immuno-ytochemistry
using confocal microscopy (Fig. 4E).
Oxidized LDLs-induced overexpression of Gclm
and HO-1 is partly mediated by ROS
Gclm and HO-1 are induced by numerous stimuli, which
have in common that they produce an oxidative stress
through ROS production (2, 11). Therefore, in order to assess
the role of the oxidized LDL-induced ROS production in the
overexpression of these genes, macrophages were incubated
in the presence of Trolox, shown to abolish the ROS produc-
tion (Fig. 2A). As shown respectively in Figures 5A and 5B, the
oxidized LDL-induced overexpression of Gclm andHO-1was
significantly reduced by the addition of Trolox. For Gclm, we
observed a 2.9- and 3.2-fold reduction in the abundance of
mRNA for OxLDLs andMoxLDLs, respectively; forHO-1, we
obtained a 2.1- and 2.5-fold reduction, respectively, for
OxLDLs and MoxLDLs. While the addition of Trolox com-
pletely abolished the accumulation of ROS induced by oxi-
dized LDLs (Fig. 2), it was unable to reduce the expression of
Gclm andHO-1 to their basal levels, supporting the hypothesis
that other pathways, independent of ROS, are involved in the
oxidized LDLs-induced overexpression of Gclm and in par-
ticular of HO-1.
Nrf2 is the major transcription factor involved
in the oxidized LDLs-induced
overexpression of Gclm and HO-1
To assess the specific contribution of Nrf2 in the LDLs-
induced overexpression of Gclm and HO-1, the RNA
FIG. 2. Oxidized LDLs induce an intracellular accumu-
lation of ROS that can be abolished by Trolox. RAW264.7
(A) or PBMC-derived macrophages (B) loaded with the
H2DCF-DA probe were stimulated with native or oxidized
LDLs (200 mg=ml) in the presence or absence of Trolox
500 mM for 6 h. The fluorescence of oxidized DCF was nor-
malized by the protein quantity and compared to control
cells arbitrarily set to 1. The graph A is the mean of three
replicates" SEM and is representative of two independent
experiments. N.S.¼ nonsignificant, ***p< 0.001 vs. control;
###p< 0.001 OxLDL vs. MoxLDL; $$$p< 0.001 absence vs.
presence of Trolox.
FIG. 3. Oxidized LDLs, but not native LDLs, induce the
activation of Nrf2. After the transfection with the ARE-luc
reporter plasmid, the macrophages were incubated with
native or oxidized LDLs (200 mg=ml) in the presence or ab-
sence of Trolox (500 mM). Results were compared to control
cells arbitrarily set to 1 and are given as the mean of six
replicates" SEM. N.S.¼nonsignificant, ***p< 0.001 vs. con-
trol; ###p< 0.001 OxLDL vs. MoxLDL; $$$p< 0.001 absence
vs. presence of Trolox.
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interference strategy was applied. The invalidation of Nrf2
led to a strong reduction of the MoxLDLs-induced over-
expression of Gclm and HO-1 (Figs. 6A and 6B). However,
whereas this invalidation totally abolished the over-
expression of Gclm, for HO-1, we still observed an over-
expression compared to control cells, suggesting that other
transcription factors activated by oxidized LDLs could
intervene in its overexpression. The oxidized-LDLs induced
overexpression of Gclm (data not shown) and HO-1 (Fig. 6C)
at the protein level was also clearly reduced by the in-
validation of Nrf2, whereas transfection of RAW264.7
macrophages with nontargeting siRNA had no effect.
NADPH oxidase plays a role in the ROS production
induced by both oxidized LDLs, but cytosolic PLA2
are involved only in MoxLDLs-treated cells
Searching to elucidate some of the molecular mechanisms
responsible for the oxidized LDLs-induced ROS production,
we showed that the use of diphenylene iodonium (DPI),
which inhibits NADPH oxidase, significantly reduced both
OxLDLs- and MoxLDLs-induced ROS accumulation (Fig.
7A). However, DPI was unable to completely abolish the ROS
production even when used at 100 mM (Fig. 7A), supporting
the fact that other ROS generating enzymes than NADPH
oxidase are implicated in oxidized LDLs-induced ROS accu-
mulation.
Several studies highlight that oxidized LDLs activate the
Ca2þ-dependent and Ca2þ-independent cytosolic phospholi-
pase A2 (cPLA2 and iPLA2, respectively), which results in the
specific release of arachidonic acid (AA) (1, 21), and the sub-
sequent activation of NADPH oxidase (34), although this
pathway of ROS production by AA is not exclusive (17).
Hence, the effect of methyl arachidonyl fluorophosphonate
(MAFP), an inhibitor of both Ca2þ-dependent and Ca2þ-in-
dependent cytosolic PLA2, on the oxidized LDLs-induced
ROS production was evaluated. As shown in Figure 7B, while
MAFP did not decrease the OxLDLs-induced generation of
ROS, it significantly reduced the MoxLDLs-generated ROS
accumulation by 43%. When exogenous AA was added to-
gether with MAFP, ROS production not only was recovered
but was even higher than with the oxidized LDLs (Fig. 7B).
The effect of MAFP on the intracellular accumulation of lipids
was also investigated. As shown in Figure 7C, no difference
FIG. 4. Gclm and HO-1 are induced by oxidized LDLs. RAW264.7 and PBMC-derived macrophages were incubated with
200 mg=ml of native or oxidized LDLs for indicated times and 6 h, respectively (A–C). The relative abundance of Gclm (A) and
HO-1 (B and C) mRNA was evaluated by real-time RT-PCR and compared to control cells arbitrarily set to 1. TBP and 18S
were used as housekeeping gene for RAW264.7 and PBMC-derived macrophages, respectively. Results are given as the mean
of four replicates" SEM. (D) Cell lysates were subjected to SDS-PAGE and immunoblotting, and the relative protein
abundance of Gclm and HO-1 was revealed by chemiluminescence. ERK2 was used as loading control. (E) RAW264.7
macrophages were treated with native or oxidized LDLs (200mg=ml) for 6 h before Gclm or HO-1 fluorescent im-
munostaining and visualization by confocal microscopy, with the nuclei in blue (Topro) and the proteins in green (Alexa 488)
(objective 63X). The experiments on RAW264.7 macrophages are representative of two independent replicates. N.S.¼non-
significant, *p< 0.05, **p< 0.01, ***p< 0.001 vs. control; #p< 0.05, ##p< 0.01, ###p< 0.001 OxLDL vs. MoxLDL.
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was observed between macrophages incubated in the pres-
ence or in the absence of MAFP for 48 h. Therefore, it seems
that PLA2 (at least cPLA2 and iPLA2) is not implicated in
foam cell formation of macrophages incubated with OxLDLs
or MoxLDLs. In conclusion, whereas NADPH oxidase is in
part implicated in both OxLDLs- andMoxLDLs-induced ROS
production, only the MoxLDLs-induced ROS generation
seems to implicate cytosolic PLA2 and the subsequent AA
release. Moreover, despite its role in MoxLDLs-induced ROS
production, cytosolic PLA2 are not implicated in the accu-
mulation of intracellular lipid droplets in macrophages incu-
bated with OxLDLs or MoxLDLs.
LDLs oxidized at both the lipid and protein moieties
by MPO behave betwixt Ox- and MoxLDLs
Based on the results obtained in Figure 7, and on the fact
that MoxLDLs, contrary to OxLDLs, are only slightly modi-
fied at the lipid level (Fig. 8A) (48), we hypothesized that the
fatty acids that are not modified and in particular arachidonic
acid (AA), can be released from the MoxLDLs by cytosolic
PLA2 and subsequently trigger ROS production. To support
this hypothesis, we generated MoxLDLs oxidized at the lipid
moiety (28), named MoxLDLs-C (see Materials and Methods;
Fig. 8A). To confirm the lipidmodification ofMoxLDLs-C, the
FIG. 5. Trolox reduces the oxidized LDLs-induced over-
expression of Gclm and HO-1. The cells were stimulated
with native or oxidized LDLs (200 mg=ml) for 6 h in
the presence or absence of Trolox 500 mM. The relative
abundance of Gclm (A) and HO-1 (B) mRNA was evalu-
ated by real-time RT-PCR and results are expressed as in
Figure 4 and given as the mean of four replicates" SEM.
N.S.¼ nonsignificant, **p< 0.01, ***p< 0.001 vs. control;
###p< 0.001 OxLDL vs. MoxLDL; $p< 0.05, $$$p< 0.001 ab-
sence vs. presence of Trolox. FIG. 6. Oxidized LDLs-induced Gclm and HO-1 over-
expression is essentially mediated by Nrf2. RAW264.7 cells
were transfected with anti-Nrf2 siRNA or nontargeting (NT)
siRNA. After stimulation with 200 mg=ml of MoxLDLs for
2 h, the relative abundance of Gclm (A) and HO-1 (B) mRNA
was evaluated by real-time RT-PCR. Results are expressed as
previously described and given as the mean of three repli-
cates" SEM. (C) RAW264.7 cells transfected with anti-Nrf2
siRNA or nontargeting (NT) siRNA were incubated with
200mg=ml of native or oxidized LDLs for 6 h. Gclm and HO-1
were visualized by confocal microscopy, as described in
Figure 4. *p< 0.05, ***p< 0.001 vs. control; $p< 0.05 siRNAþ
MoxLDL vs. MoxLDL or NT siRNAþMoxLDL, $$$p< 0.001
siRNAþMoxLDL vs. MoxLDL or NT siRNAþ MoxLDL.
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extent of lipid peroxidation in NatLDLs, MoxLDLs, and
MoxLDLs-C was determined by a fluorescence-based meth-
od, according to Yagi et al. (42) (Fig. 8A). Zouaoui Boudjeltia
et al. (48) already showed that lipid peroxidation in OxLDLs
was much more intense in comparison to NatLDLs (Fig. 8A).
In striking contrast, lipid peroxidation was only slightly in-
creased inMoxLDLs, supporting the statement thatMoxLDLs
mainly used in this work are almost not modified at the lipid
level. The analysis of MoxLDLs-C showed elevated levels of
lipid peroxidation in comparison to MoxLDLs, but this in-
crease was lower than in OxLDLs (Fig. 8A). Therefore, lipid
oxidation of MoxLDLs-C is intermediate between OxLDLs
FIG. 7. Effects of DPI and MAFP on ROS production in-
duced by oxidized LDLs. RAW264.7 macrophages loaded
with the H2DCF-DA dye were stimulated with native or ox-
idized LDLs (200 mg=ml), and=or AA (20 mM) in the presence
of DPI (50mM or 100mM) (A) or MAFP (50mM, B). After
30min, the fluorescence of oxidized DCF was measured and
expressed as described in Figure 1. (C) RAW264.7 macro-
phages were incubated with LDL for 48 hours in the presence
or absence of MAFP (50mM) before lipid staining by Oil Red
O. Results are given as the mean of three replicates" SEM.
N.S.¼nonsignificant, *p< 0.05, **p< 0.01, ***p< 0.001 vs.
control; ###p< 0.001 OxLDL vs MoxLDL; $$p< 0.01 absence
vs. presence of the inhibitor, $$$p< 0.001 absence vs. presence
of the inhibitor or MAFP vs MAFPþAA.
FIG. 8. Effects of the lipid peroxidation extent of LDLs on
foam cell formation and on intracellular ROS accumula-
tion. Lipid peroxidation of native and oxidized LDLs was
evaluated by a fluorescence-based method as described in
the Materials and Methods. The extent of lipid peroxidation
was expressed in comparison to NatLDLs arbitrarily set to 1
(A). RAW264.7 macrophages were incubated for 48 h with
native or oxidized LDLs (200mg=ml), stained with Oil Red O,
and the absorbance of the staining was normalized by the
quantity of cells (B). Cells loaded with the H2DCF-DA dye
were stimulated with native or oxidized LDLs (200 mg=ml).
After 30min, the fluorescence of oxidized DCF was mea-
sured and expressed as described in Figure 1 (C). Results are
given as the mean of three replicates" SEM. N.S.¼nonsig-
nificant, *p< 0.05, ***p< 0.001 vs. control; #p< 0.05,
###p< 0.001 OxLDL or MoxLDL-C vs. MoxLDL; (1) based on
the results of Zouaoui Boudjeltia et al. (48).
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and MoxLDLs. In the same way as the incubation with
OxLDLs or MoxLDLs, the treatment of RAW264.7 macro-
phages with MoxLDLs-C for 48 h also induced a significant
accumulation of intracellular lipid droplets (Fig. 8B). Fur-
thermore, we showed that the MoxLDLs-C-induced ROS
production after 30min was lower when compared to
MoxLDLs, but higher compared to OxLDLs (Fig. 8C). Inter-
estingly, this result suggests that ROS production is inversely
related to the extent of lipid peroxidation observed in the
different types of modified LDL (Fig. 8A).
Discussion
The oxidative modifications of LDLs contribute to the path-
ogenesis of atherosclerosis, and the presence of cholesterol-
loaded macrophages is an important feature throughout the
development of the lesion. However, in vivo neither the
mechanisms nor the site of LDLs oxidation are totally eluci-
dated. Oxidative modifications of LDLs are often produced
in vitro by the use of copper ions. However, in 1996, Berliner
and Heinecke already provided data questioning the role of
copper in in vivo LDL oxidation (3). This was sustained
afterwards by numerous data and studies. First of all, low
concentrations of albumin, the most abundant protein in
plasma, inhibit metal ion-dependent LDL oxidation, and this
protein also avidly binds free copper (37). Indeed, there is no
convincing evidence that either free iron or copper do exist in
plasma, and extracellular free metal ions are, therefore, un-
likely to be present in normal arterial tissue. Metal ions might
become available under pathologic conditions, however,
perhaps as a result of dying cells accumulating in advanced
atherosclerotic lesions. On the other hand, even if copper
could have a potential role in LDL oxidation in vivo, the
concentrations of copper sulfate currently used in vitro to
oxidize LDL (e.g., 10 to 20 mM), largely exceed physiological
concentrations (47). Ziouzenkova and collaborators notably
underlined that LDL oxidized with copper sulfate used at the
concentration of 0.03mM, which is in the range of physiolog-
ical concentrations, display major differences in composition
compared to LDL oxidized using copper sulfate at 10 mM (47).
Concomitantly with numerous other studies, these authors
emphasized that it is uncertain if this in vitro model reflects
any aspects of LDL oxidativemodification in vivo. In 2003, this
was also corroborated by Zarev and collaborators who
highlighted that the use of low concentrations of copper, far
below the saturation of the LDL binding sites and capable to
initiate low LDL oxidation rates, could be more relevant re-
garding in vivo LDL oxidation (46). They also showed that
different concentrations of copper not only lead to significant
differences in LDL oxidation kinetics, but also to different
forms of oxidized LDL with specific physicochemical and
probably biological features (46).
Alternatively, oxidizing enzymes present in pro-inflam-
matory conditions have been proposed to play a role in the
in vivo oxidation of LDL, such as lipoxygenases (in particular
15-lipoxygenase) (41), NADPH oxidase (13), and MPO, that
was privileged in this work. MPO is found as a catalytically
active enzyme within atherosclerotic lesions, as evidenced by
the presence of immuno-detected MPO, its specific products,
as well as MPO-modified LDLs, suggesting a role for this
enzyme in the in vivo modifications of LDLs (8, 12, 28).
Moreover, in atherosclerotic lesions, MPO colocalizes with
macrophage-derived foam cells (8) and is able to strongly
bind to Apo-B100 of LDL (5). Finally, using mass spectrom-
etry, Leeuwenburgh et al. detected a 100-fold selective in-
crease in o,o’-dityrosine levels in LDL isolated from human
atherosclerotic lesions compared to circulating LDLs. Al-
though in vitro incubation of LDL with copper increased both
o-tyrosine and m-tyrosine, little change in the level of o,o’-
dityrosine was observed. In contrast, o,o’-dityrosine was
selectively produced in LDL oxidized with tyrosyl radical
generated by myeloperoxidase (20). Therefore, the detection
of a selective increase in o,o’-dityrosine levels with limited
changes in either o-tyrosine or m-tyrosine in LDL isolated
from human vascular lesions, is consistent with the hypoth-
esis that oxidative damage in human atherosclerosis is
mediated in part by tyrosyl radical generated by myeloper-
oxidase. MPO is therefore considered as one of the potential
enzymes implicated in LDL oxidation in vivo (32).
However, in striking contrast with a deleterious role for
MPO in atherogenesis through its implication in LDL oxida-
tion, MPO-deficient mice developed 50% larger atheroscle-
rotic lesions than WT mice (4). Nonetheless, MPO levels are
5-fold to 10-fold higher in humans than in mice and MPO
regulation may also differ significantly. Moreover, in contrast
to human atherosclerotic lesions that readily stain forMPO (8)
and show clear evidence of 3-chlorotyrosine (12), only small
amounts of MPO are found within murine atherosclerotic
lesions and the 3-chlorotyrosine levels observed in the mouse
are barely above the limit of detection (4), suggesting limited
catalytically active MPO in the artery wall in mice. Therefore,
although mouse models have provided important insights
into the pathogenesis of atherosclerosis, the limited levels of
MPO and 3-chlorotyrosine observed in mouse atheroma
might at first glance suggest that the murine model has lim-
ited relevance for studies of MPO in atherosclerosis.
In order to better evaluate the role of humanMPO (h-MPO)
in atherogenesis, McMillen et al. generated transgenic mice
that expressed h-MPO exclusively in macrophages (27). This
cell-specific expression of h-MPO increased the average size of
the atherosclerotic lesions by 2.3-fold compared to mice
transplanted with WT bone marrow. The larger atheroscle-
rotic lesions observed in MPO-deficient mice and in trans-
genic mice expressing h-MPO in macrophages strongly
suggest thatMPO fromneutrophils andmonocytes play a role
in atherogenesis that is distinct from that of macrophage-
associated MPO in the artery wall. This supports the
hypothesis that macrophage-specific expression of MPO is
atherogenic and raises the possibility that lipoprotein oxida-
tion via MPO is an important mechanism.
Copper and myeloperoxidase induce some distinct bio-
chemical alterations of LDLs (44). Actually, the oxidation of
LDLs with copper ions causes important modifications of
both the lipid and protein moieties of the LDLs (46). On the
other hand, MoxLDLs used in this work are predominantly
modified only in their protein moiety, with limited modifi-
cations of the lipids (24, 48). Moreover, the concentrations of
MoxLDLs used (200 mg=ml) correspond to pathophysiological
concentrations indeed observed in patients suffering from
COPD (49) or undergoing dialysis (39) and prone to cardio-
vascular disease.
Interestingly, the signal transduction pathways activated
by OxLDLs are relatively well-known and the active com-
pounds identified up to now are generally lipids (26). Much
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less information is available about MoxLDLs and although
numerous studies have characterized the cellular responses
either to OxLDLs or, to a lesser extent, to MoxLDLs, com-
parative studies are much more difficult to find. For these
reasons, in this study, the differential effects of OxLDLs and
MoxLDLs were compared in RAW264.7 macrophages and the
results were partly validated in human PBMC-derived macro-
phages.
First of all, we showed that macrophages incubated with
MoxLDLs accumulate more intracellular lipid droplets than
when incubated with OxLDLs. Given the differential modi-
fications of ApoB-100 by copper and the MPO–H2O2–Cl
-
system (44), a differential affinity for or a differential recog-
nition by the diverse scavenger receptors could be a possible
explanation to interpret this distinction. Although the scav-
enger receptors for OxLDLs are well described and comprise
predominantly SR-A and CD36, those for MoxLDLs are not
yet unambiguously identified. Nevertheless, in vitro studies
on THP-1 macrophages have shown that class B scavenger
receptors, namely CD36 and SR-BI, play a role in the inter-
nalization of MoxLDLs (25). The specific scavenger receptors
implicated in the internalization of OxLDLs and more par-
ticularly of MoxLDLs should certainly deserve more atten-
tion. On the other hand, the incubation of macrophages with
OxLDLs or MoxLDLs also differentially affects their mor-
phology. RAW264.7 macrophages incubated with MoxLDLs
display a characteristic spreaded morphology while they re-
main rounded in the presence of OxLDLs. Although OxLDLs
could affect cytoskeletal components, such as actin or vi-
mentin (9, 31), the effect of MoxLDLs on these proteins is still
not known, and could explain the observed differential mor-
phology.
Second, in view of the biochemical differences between
OxLDLs and MoxLDLs, it is not surprising to observe dif-
ferences between OxLDLs and MoxLDLs in the activation of
Nrf2 and the induction of Gclm and HO-1, with a stronger
response towards MoxLDLs. The protective and stress-
induced Nrf2 pathway is functionally critical and tightly
controlled in the cell. Its activation leads to the generation of
metabolizing and scavenging systems to remove excessive
ROS, which are detrimental and affect cells functions. Gclm
constitutes the rate-limiting enzyme in glutathione synthesis,
the most important and most abundant endogenous antioxi-
dant (11). GSH participates in many cellular reactions in-
cluding antioxidant defenses of the cell, but also cell signaling
(11, 15). Indeed, alterations in the redox balance by exposure
to ROS cause changes in the reduced=oxidized glutathione
(GSH=GSSG) equilibrium, which potentially affect a number
of target proteins by causing oxidation at specific cysteine
residues, such as the Nrf2 cytoplasmic repressor Keap1 (38).
As a consequence, Gclm, as the rate-limiting enzyme in GSH
synthesis, could play a crucial role in maintaining an optimal
GSH=GSSG balance, providing a protective antioxidant
mechanism against oxidative stress-induced cellular dys-
function. On the other hand, contrary to Gclm, the beneficial
role of HO-1 and its by-products in atherogenesis has been
largely described (7, 29). In vascular cells and macrophages,
HO-1 is induced by most of the well-established cardiovas-
cular risk factors, including oxidized LDLs (43), and Nrf2 is
essential for its overexpression (6, 14). The proposed mecha-
nism by which HO-1 exerts its cytoprotective effects includes
its ability to degrade pro-oxidative heme, to release biliverdin
and subsequently convert it into bilirubin, both of which have
antioxidant properties, and to generate carbon monoxide,
which has antiproliferative, anti-inflammatory and vasodila-
tory properties (7, 29). Therefore, HO-1 participates to the
anti-atherogenic defence systems of the macrophages, nota-
bly by increasing antioxidant protection in atherosclerotic
lesions.
Finally, another and very important distinction between
OxLDLs and MoxLDLs was observed in the intensity of the
induced oxidative stress. As we have shown by the use of
Trolox, the oxidized LDL-induced accumulation of ROS is
mainly responsible for the activation of Nrf2 and for the
overexpression of Gclm and HO-1, which suggests that the
differential oxidative stress generated by OxLDLs and
MoxLDLs is the leading cause of the subsequent variations
observed in the response to these two types of LDLs. We
showed that although NADPH oxidase is implicated in both
oxidized LDLs-induced ROS accumulation, the release of AA
by some PLA2 isoforms, possibly cPLA2 and=or iPLA2, only
takes part in the MoxLDLs-induced activation of NADPH
oxidase. This is not surprising since MoxLDLs contrary to
OxLDLs, are not affected in their lipid moiety (24, 48), which
means that the fatty acids and thus AA, are not modified and
can be cleaved by PLA2. This model was supported by the
production ofMoxLDLs oxidized not only at the protein level,
but also at the lipid level, named MoxLDLs-C. Indeed, in
specific conditions, MPO can also modify the lipid moiety of
the LDL. Fluorescence-based analysis of LDLs showed that
the extent of lipid peroxidation in MoxLDLs-C was interme-
diate between OxLDLs andMoxLDLs. In agreement with our
hypothesis, the MoxLDLs-C-induced ROS production was
smaller than the one caused by MoxLDLs, but largely higher
than the OxLDLs-induced ROS accumulation, indicating that
there seems to be an inverse relation between lipid perox-
idation in modified LDL and the capacity to induce ROS
production. In conclusion, the nonoxidized lipids of LDLs
seem to be implicated in the LDLs-induced ROS production.
In the presence of NatLDLs, we could hypothesize that their
recognition by the LDL-R and not by the scavenger receptors
prevents this ROS accumulation, but also that cPLA2 and=or
iPLA2, would not be activated (21). This observation under-
lines an important difference in the ROS-producing mecha-
nisms between OxLDLs and MoxLDLs, which could in part
explain the distinct cellular responses observed in this study
between both types of LDLs.
In conclusion, this study highlights that at concentrations
observed in patients suffering from COPD or in patients
under dialysis, the more relevant MoxLDLs that are only
modified in their protein moiety, induce a stronger antioxi-
dant and protective response than OxLDLs in macrophages,
as revealed by the activation of the Nrf2 pathway. As the
oxidative stress plays an important role in the pathogenesis of
many diseases, including atherosclerosis, the understanding
of redox regulation and the effects of disturbed redox ho-
meostasis on cell functions could be used to develop new
strategies for the treatment or prevention of those diseases. In
this way, the differential generation of ROS and the distinct
ROS-producing mechanisms induced by OxLDLs and
MoxLDLs, should be taken into account, and all the data
obtained until now with copper oxidized-LDLs carefully re-
evaluated taking into consideration physiologically more
relevant oxidized LDLs.
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Abbreviations Used
AA¼ arachidonic acid
ARE¼ antioxidant response element
COPD¼ chronic obstructive pulmonary disease
cPLA2¼ calcium-dependent cytosolic
phospholipase A2
DPI¼diphenylene iodonium chloride
Gclm¼ glutamate cysteine ligase, regulatory subunit
GSH¼ reduced glutathione
GSSG¼ oxidized glutathione
H2DCF-DA¼ 2’,7’-dichlorodihydrofluorescein diacetate
HO-1¼heme oxygenase-1
iPLA2¼ calcium-independent cytosolic
phospholipase A2
LDL-R¼LDL receptor
LDLs¼ low-density lipoproteins
MAFP¼methyl arachidonyl fluorophosphonate
M-CSF¼macrophage colony stimulating factor
MoxLDLs¼myeloperoxidase-oxidized LDLs
NatLDLs¼native LDLs
Nrf2¼NF-E2-related factor 2
OxLDLs¼ copper-oxidized LDLs
PBMC¼peripheral blood mononuclear cells
rhMPO¼ recombinant human myeloperoxidase
ROS¼ reactive oxygen species
Trolox¼ 6-hydroxy-2,5,7,8-tetramethylchromane-
2-carboxylic acid
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